Market Size of Scleroderma Therapeutics Industry
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Scleroderma Therapeutics Market Analysis
The scleroderma therapeutics market is expected to register a CAGR of 5.7% over the forecast period.
The COVID-19 pandemic negatively impacted the global scleroderma therapeutics market. An article published by the journal Lancet Rheumatology in August 2022 reported that COVID-19 led to restrictions that posed a severe challenge to managing pre-existing comorbidities like scleroderma, as doctors and healthcare professionals were busy treating and minimizing COVID-19 infections. However, with the substantial decrease in COVID-19 cases and resumptions of healthcare services, the scleroderma therapeutics market is expected to regain its growth pace. It is projected to show stable growth over the forecast period.
The factors driving the growth of this market are the rising prevalence of scleroderma and the development of novel drug therapies by pharmaceutical companies. An article published by European Medical Journal in May 2022 reported that localized scleroderma (LS) and systemic sclerosis (SSC) are increasing. The incidence of localized scleroderma (LS) in the United States is estimated to be 2.7 out of 100,000 persons. The incidence of systemic sclerosis worldwide is estimated to be 1.4 out of 100,000 person-years in 2021. Thus, the high incidence of this disease is increasing the demand for scleroderma therapeutics, thereby driving the growth of the studied market.
Technological developments have enabled pharmaceutical companies to focus on developing novel drugs. In October 2022, Scleroderma News reported that LMCD1 protein may be a potential novel therapeutic target for patients with SSc-ILD. LMCD1 protein is present at higher levels in the lungs of patients with interstitial lung disease (ILD) linked to systemic sclerosis (SSc) than in healthy individuals. Hence, it is a candidate target for the treatment of the disease. Such novel studies and research for developing novel therapeutics are driving the growth of the studied market.
Similarly, Drug Target Reviews in March 2022 reported that a unique macrophage, an immune cell that removes bacteria or dead cells, plays a vital role in the chronic inflammation and scarring in the lungs and skin of people with scleroderma, or systemic sclerosis. Scientists are targeting this macrophage for the development of drugs. Such studies are leading to the development of novel approaches for treating scleroderma, thereby driving the growth of the studied market.
Thus, due to the rising prevalence of scleroderma and the development of novel drug therapies by pharmaceutical companies, the studied market is expected to witness significant growth over the forecast period. However, regulatory and reimbursement issues may slow down the development of the market.
